Healthy CD4+ T Lymphocytes are Not Affected by Targeted Therapies Against the PI3K/Akt/mTOR Pathway in T-cell Acute Lymphoblastic Leukemia
Author
McCubrey, James A.
Date
2016-08-23
Citation:
APA:
McCubrey, James A.. (August 2016).
Healthy CD4+ T Lymphocytes are Not Affected by Targeted Therapies Against the PI3K/Akt/mTOR Pathway in T-cell Acute Lymphoblastic Leukemia.
Oncotarget,
(7:34), p.. Retrieved from
http://hdl.handle.net/10342/9592
MLA:
McCubrey, James A..
"Healthy CD4+ T Lymphocytes are Not Affected by Targeted Therapies Against the PI3K/Akt/mTOR Pathway in T-cell Acute Lymphoblastic Leukemia". Oncotarget.
7:34. (.),
August 2016.
May 23, 2022.
http://hdl.handle.net/10342/9592.
Chicago:
McCubrey, James A.,
"Healthy CD4+ T Lymphocytes are Not Affected by Targeted Therapies Against the PI3K/Akt/mTOR Pathway in T-cell Acute Lymphoblastic Leukemia," Oncotarget 7, no.
34 (August 2016),
http://hdl.handle.net/10342/9592 (accessed
May 23, 2022).
AMA:
McCubrey, James A..
Healthy CD4+ T Lymphocytes are Not Affected by Targeted Therapies Against the PI3K/Akt/mTOR Pathway in T-cell Acute Lymphoblastic Leukemia. Oncotarget.
August 2016;
7(34)
. http://hdl.handle.net/10342/9592. Accessed
May 23, 2022.
Collections